Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/1999
10/21/1999WO1999052847A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999WO1999052562A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
10/21/1999WO1999052561A1 Inhibition of xenoreactive antibodies
10/21/1999WO1999052559A1 OPHTHALMIC COMPOSITION COMPRISING A β-BLOCKER
10/21/1999WO1999052555A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors
10/21/1999WO1999052554A1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
10/21/1999WO1999052553A1 Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition
10/21/1999WO1999052548A2 Conjugate vaccines for the prevention of dental caries
10/21/1999WO1999052546A2 A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
10/21/1999WO1999052535A1 Novel therapeutic agents interfering in neutrophil migration
10/21/1999WO1999052534A1 Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways
10/21/1999WO1999052533A1 Compositions comprising ethisterone or its derivatives
10/21/1999WO1999052532A1 Method for reducing central nervous system impairment
10/21/1999WO1999052531A1 New treatments for nervous disorders
10/21/1999WO1999052530A1 Antibacterial agents
10/21/1999WO1999052529A1 Antioxidant stabilizer system for pharmaceutical formulations
10/21/1999WO1999052528A1 Pharmaceutical preparations containing hydrosoluble ketoprofen salts and their application
10/21/1999WO1999052527A1 Use of a porphyrin for producing a medicine reducing the number of eosinophils
10/21/1999WO1999052526A1 Carvedilol-galenics
10/21/1999WO1999052525A1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/21/1999WO1999052524A1 Use of cannabinoids as anti-inflammatory agents
10/21/1999WO1999052523A2 Flutamide compositions and preparations
10/21/1999WO1999052522A1 Protection of the nervous system using sodium channel blockers
10/21/1999WO1999052521A1 Spisulosine compounds having antitumour activity
10/21/1999WO1999052520A1 Ionic aqueous composition containing levomenthol
10/21/1999WO1999052519A2 Methods for treating neuropsychiatric disorders
10/21/1999WO1999052518A2 New treatments for nervous disorders
10/21/1999WO1999052517A2 Composition comprising ketanserin and l-carnitine or an alkanoyl l-carnitine for the treatment of crps
10/21/1999WO1999052516A2 Acylpeptide protease inhibitors to enhance cognitive function
10/21/1999WO1999052515A2 Use of organophosphoric compounds for the therapeutic and preventative treatment of infections
10/21/1999WO1999052514A2 Pharmaceutical composition and combination preparation for immunosuppressive therapy
10/21/1999WO1999052512A1 Coated starch capsules and a process for producing them
10/21/1999WO1999052508A1 Method for the treatment of asthma
10/21/1999WO1999052504A1 Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants
10/21/1999WO1999052495A1 External preparations for treating dry skin
10/21/1999WO1999052493A2 Compounds that inhibit the binding of integrins to their receptors
10/21/1999WO1999052365A1 Anticancer agents
10/21/1999WO1999052363A1 Method of regulating appetite and metabolism
10/21/1999WO1999046254A3 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis
10/21/1999WO1999046245A3 PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
10/21/1999WO1999045920A3 The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
10/21/1999WO1999045905A3 Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
10/21/1999WO1999044624A3 Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
10/21/1999WO1999043676A3 6,9-disubstituted 2-[trans-(4- aminocyclohexyl) amino]purines
10/21/1999WO1999042593A8 Compositions and methods for sensitizing and inhibiting growth of human tumor cells
10/21/1999WO1999040061A3 Novel dihydroxyhexanoic acid derivatives
10/21/1999WO1999039712A9 Substituted semicarbazides and the use thereof
10/21/1999WO1999039707A8 Metal-thiols as immunomodulating agents
10/21/1999WO1999038501A9 Method of regulating glucose metabolism, and reagents related thereto
10/21/1999WO1999037623A3 Sulphonamide derivatives for treatment of cns disorders
10/21/1999WO1999036553A3 Regulation of biological events using multimeric chimeric proteins
10/21/1999WO1999035156B1 Novel macrolides
10/21/1999WO1999033454A3 S-procyclidine for treating urinary incontinence
10/21/1999WO1999033452A3 Amine-containing copolymers as bile acid sequestrants
10/21/1999WO1999030738A3 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
10/21/1999WO1999030157A9 Neuropilins in methods for diagnosis and prognosis of cancer
10/21/1999WO1999026927A3 Metabotropic glutamate receptor antagonists for treating central nervous system diseases
10/21/1999WO1995026768A9 Methods for treating pulmonary vasoconstriction and asthma
10/21/1999DE19916896A1 Particles for chelating metal ions, useful in cosmetic, pharmaceutical and food products and products for treating liquids, especially water
10/21/1999DE19848597A1 Stabilized compositions useful for stimulating collagen neogenesis in treatment of bone defects
10/21/1999DE19827633A1 Production of N-methyl-N-(1-phenyl-2-(3-hydroxypyrrolidino)ethyl)-2,2-diphenylacetamide enantiomers, e.g. with antiinflammatory, analgesic and diuretic activity
10/21/1999DE19825585A1 Treating and preventing viral, fungal or parasitic infections in humans and animals
10/21/1999DE19818614A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817511A1 Treating or preventing skin or mucosal virus infections, e.g. by herpes viruses, using pantothenic acid, dexpanthenol or derivatives
10/21/1999DE19817461A1 New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817459A1 New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc.
10/21/1999DE19817295A1 Use of compounds that inhibit water-induced removal of endogenous or artificially applied cis- or trans-urocanic acid from human skin in cosmetic or dermatological compositions
10/21/1999DE19817265A1 Treating hepatitis B using new or known dihydropyrimidine derivative antiviral agents
10/21/1999DE19817264A1 New dihydropyrimidine derivatives and their corresponding mesomers useful as antiviral agents
10/21/1999DE19817262A1 New dihydropyrimidine derivatives and their corresponding mesomers useful in treatment of hepatitis
10/21/1999DE19817177A1 Preparation of plant derived polysaccharides with immune system stimulating activity
10/21/1999DE19816983A1 New bicyclic heteroaromatic amidine or nitrile compounds, used as thrombin inhibitors, antithrombotic agents or intermediates
10/21/1999DE19816882A1 Use of known and new triazolone derivatives as medicaments, especially for treatment of neurodegenerative disorders and cerebral ischemia
10/21/1999DE19816880A1 New diaryl substituted heterocyclic compounds are AMPA receptor antagonists useful in treatment of neurodegenerative disorders and cerebral ischemia
10/21/1999DE19816857A1 Novel adenosine antagonists useful in treatment of e.g. neurodegenerative, pulmonary, renal and cardiovascular disorders
10/21/1999DE19816780A1 New tryptamine derivatives useful as antibacterial agents for treating infections in humans and especially animals
10/21/1999DE19816624A1 Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel New substituted indolinones, their preparation and their use as medicaments
10/21/1999DE19816492A1 Extrakt aus Copalchirinde, Coutareagenin und Neoflavonoide und deren Verwendung zur Behandlung von Diabetes Typ II Copalchi bark extract, Coutareagenin and neoflavonoids and their use for the treatment of type II diabetes
10/21/1999DE19806581A1 Sequenzen eines Ih-Ionenkanals und deren Verwendung Sequences of Ih ion channel and their use
10/21/1999CA2634698A1 New treatments for nervous disorders
10/21/1999CA2328878A1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/21/1999CA2328729A1 Method of regulating appetite and metabolism
10/21/1999CA2328360A1 Improvements in or relating to protease inhibitors
10/21/1999CA2328344A1 Method for the treatment of asthma
10/21/1999CA2328252A1 Receptor ligands
10/21/1999CA2328250A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999CA2328245A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
10/21/1999CA2328211A1 Substituted pyrrolidine hydroxamate metalloprotease inhibitors
10/21/1999CA2328157A1 Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway
10/21/1999CA2328126A1 Spisulosine compounds having antitumour activity
10/21/1999CA2328075A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors
10/21/1999CA2327884A1 Novel therapeutic agents interfering in neutrophil migration
10/21/1999CA2327791A1 7-hexanoyltaxol and methods for preparing the same
10/21/1999CA2327782A1 Azabicyclic 5ht1 receptor ligands
10/21/1999CA2327708A1 Antioxidant stabilizer system for pharmaceutical formulations
10/21/1999CA2327516A1 Programmed cell death and caspase-12
10/21/1999CA2327488A1 Amidine compounds
10/21/1999CA2327477A1 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
10/21/1999CA2327450A1 Paroxetine maleate
10/21/1999CA2327431A1 Pharmaceutical composition
1 ... 6425 6426 6427 6428 6429 6430 6431 6432 6433 6434 6435 6436 6437 6438 6439 6440 6441 6442 6443 6444 6445 ... 7860